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Abstract: Ipsilateral breast tumor recurrence (IBTR) is an increasingly common clinical challenge. IBTRs include True Recurrences 
(TR; persistent disease) and New Primaries (NP; de novo tumors), but discrimination between these is difficult. We assessed tumor 
infiltrating leukocytes (TIL) as biomarkers for distinguishing these types of IBTR using primary tumors and matched IBTRs from 
24 breast cancer patients, half of which were identified as putative TRs and half as NPs using a previously reported clinical algorithm. 
  Intratumoral lymphocyte populations (CD3, CD8, CD4, CD25, FOXP3, TIA1, CD20) and macrophages (CD68) were quantified by 
immunohistochemistry in each tumor. Compared to matched primaries, TRs showed significant trends towards increased CD3+ and 
CD8+ TIL, while these populations were often diminished in NPs. Comparison of IBTRs showed that TRs had significantly higher   levels 
of CD3+ (P = 0.0136), CD8+ (P = 0.0092), and CD25+ (P = 0.0159) TIL than NPs. We conclude that TIL may be a novel diagnostic 
biomarker to distinguish NP from TR IBTRs.
Keywords: breast cancer, ipsilateral breast tumor recurrence, true recurrence, new primary, immune response, tumor infiltrating 
leukocytesWest et al
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Introduction
In  the  modern  era  of  breast  conservation,  ipsilat-
eral breast tumor recurrence (IBTR) represents an 
increasingly  common  clinical  dilemma,  occurring 
in 5%–20% of women with early stage breast can-
cer treated with breast conserving therapy.1–10 Since 
some breast recurrences can confer high risk of dis-
tant metastasis and mortality,11,12 improved methods 
to differentiate prognostic subgroups are needed to 
individualize risk estimates and treatment decisions 
for patients with IBTR.
Two distinct entities of IBTR have been described: 
True Recurrence (TR) and New Primary (NP) tumors 
arising in the ipsilateral breast.9 TRs have been sug-
gested to be cases of re-growth of malignant cells 
not completely eradicated by initial treatment. This 
type of relapse is hypothesized to be distinct from NP 
tumors that arise in the ipsilateral breast away from 
the original breast tumor, representing de novo can-
cers arising from residual breast tissue. This distinc-
tion suggests that an NP IBTR is independent of the 
primary lesion and may have different clinical fea-
tures and prognosis compared to a TR.9
Clinical distinctions between TR and NP IBTR 
are  made  routinely  in  the  clinic  on  the  basis  of 
  non-standardized  criteria.  The  varied  proportions 
of IBTR cases classified as TR versus NP and the 
diverse findings in survival prognoses among pro-
spective  and  retrospective  studies  reflect  the  wide 
variation in the classification methods used.2,4,6,8,10,13–19 
TRs are thought to result from a failure of initial 
therapy  to  achieve  local  control  and  often  herald 
metastatic  recurrence,  warranting  consideration  of 
aggressive systemic   therapy. By contrast, NPs have 
no  such  implications  and  are  often  treated  more 
conservatively.
Location in the vicinity of the index tumor bed has 
been traditionally used as one of the most important 
factors to define a relapse as a TR. However the term 
“same location” or “in the vicinity of the index tumor” 
may be interpreted differently by different observers, 
and it is possible for a new primary to occur in the 
same vicinity. Pathological parameters can also pro-
vide some measures of biological similarity between 
primary  and  recurrent  tumors  through  assignment 
of  histological  type,  grade,  and  estrogen  receptor 
(ER)  status.  However,  these  parameters  also  have 
  significant limitations. For example, most parameters 
have  limited  numbers  of  categories  (for  example, 
most tumors are ductal type), tumor evolution during 
progression and treatment can alter features such as 
grade, and diagnostic assays (such as for ER status) 
can differ over time and between institutions.
Host immunity plays an important and complex 
role in the regulation of tumor progression,20 and the 
presence of tumor-infiltrating leukocytes (TIL) at 
the time of initial diagnosis is believed to reflect the 
host anti-tumor immune response. Breast cancers are 
often immunogenic and drive antigen-specific lym-
phocyte responses.21–24 For example, clonal expan-
sion of B cells and tumor antigen-specific memory 
T cells within the tumor and bone marrow of breast 
cancer patients has been reported.23,24 Because TR 
and NP IBTRs are thought to have distinct origins, 
they  could  be  expected  to  differ  with  respect  to 
patterns of mutation and gene expression profiles, 
and by extension their spectra of tumor antigens. 
Given the exquisite antigen specificity of adaptive 
immune  responses,  tumor-specific  host  immunity 
may represent a useful diagnostic tool for the dis-
crimination of TR and NP IBTRs. For example, if 
a primary tumor elicits an antigen-specific immune 
response with production of memory T or B lym-
phocytes, a subsequent TR would likely be recog-
nized by these memory cells and their progeny. In 
contrast, an NP lesion may not be recognized by 
memory cells specific to the original tumor, based 
on  antigenic  differences.  It  is  therefore  plausible 
to  consider  the  hypothesis  that  the  intratumoral 
immune response might show reproducible patterns 
of  change  between  primary  tumors  and  relapses, 
and between different types of relapse, and so may 
represent a useful diagnostic tool for the discrimi-
nation of TR and NP type IBTRs.
To begin to address this possibility, this study com-
pares  distributions  of  TIL  between  primary  breast 
tumors and matched IBTRs and evaluates the utility 
of several TIL phenotypes as biomarkers to differen-
tiate clinically classified TR from NP IBTRs.
Materials and Methods
Study subjects
The  British  Columbia  Cancer  Agency  (BCCA) 
Breast Cancer Outcomes Unit database was used to immune response to in-breast tumor recurrence
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identify 289 cases of patients with an initial diagnosis 
of pT1–T2, N0–1, M0 breast cancer who   developed 
pathologically  confirmed  IBTR,  defined  as  the 
first  recurrence  occurring  in  the  ipsilateral  breast. 
  Clinical characteristics of the entire cohort have been 
  previously reported.25 The current exploratory study 
was based on a subset (8%) of the entire case cohort 
that originated at two of thirty one hospital centers 
across British Columbia where paraffin blocks cor-
responding  to  both  index  and  IBTR  were  readily 
accessible.  The  exploratory  study  cohort  details 
(n = 24 cases) are summarized in Table 1. The study 
was approved by the BCCA and University of British 
Columbia Research Ethics Board.
Clinical classification of true recurrence 
vs. new primary
To  classify  IBTR  cases  as  either  TR  or  NP,  we 
applied a consistent decision rule algorithm18 based 
on sequential consideration of typical features used 
to distinguish IBTRs in the clinic but with predefined 
criteria for change in histological type, grade, estro-
gen receptor (ER) status and tumor location (Fig. 1). 
In this algorithm, only a change of the Nottingham 
grade from III in the primary tumor to I in the IBTR 
was considered significant so as not to capture dis-
ease that had dedifferentiated over time. Likewise, 
ER  status  was  considered  different  if  the  primary 
tumor  was  ER-negative  and  the  IBTR  was  ER- 
positive. Location, determined by review of the clini-
cal descriptions and breast imaging reports including 
mammography and ultrasound, was scored as dif-
ferent if more than 3 centimeters from the primary 
tumor location.
Pathology review, tissue microarray 
construction, and immunohistochemisty
Each of the 24 cases included paraffin blocks of the 
primary and IBTR tumors, with associated data from 
assessment  of  hematoxylin  and  eosin  (H&E)  sec-
tions by a breast histopathologist (PHW). All cases 
were re-reviewed to categorize morphological simi-
larity and to select areas for coring of corresponding 
blocks. To construct the tissue microarray (TMA), 
duplicate tissue cores (0.6 mm diameter) were taken 
from central cellular areas of each tumor with a tis-
sue arrayer instrument (Beecher Instruments, Silver 
Spring,  MD,  USA).  Immunohistochemistry  (IHC) 
was performed for markers of adaptive (CD3, CD8, 
CD4, CD25, FOXP3, TIA1, CD20) or innate (CD68) 
immune responses on deparaffinized sections from 
TMAs  using  a  Ventana  Discovery  XT  autostainer 
(Ventana, Tucson, AZ). Information on primary anti-
bodies  is  provided  in  Table  2.  Ventana’s  standard 
CC1   protocol was used for antigen retrieval. TMA 
sections  were  incubated  with  primary  antibodies 
for 60 minutes at room temperature followed by the 
appropriate  crossadsorbed,  biotinylated  secondary 
antibody (Jackson Immunoresearch, West Grove, PA) 
for 32 minutes. Antibodies were detected using the 
DABMap kit   (Ventana). Slides were counterstained 
with    hematoxylin  and  coverslipped  manually  with 
Cytoseal-60.
Of the adaptive (lymphocyte) markers we assessed, 
CD3 identifies all T cells; CD8 and CD4 are lineage 
markers  expressed  primarily  on  the  cytotoxic  and 
helper T cell subsets, respectively; CD25 and FOXP3 
are commonly used as markers of immunosuppres-
sive regulatory T cells, although these markers are 
also expressed transiently by activated conventional 
T cells; TIA1 is a component of cytolytic granules 
and primarily identifies CD8+ T cells with cytotoxic 
potential; and CD20 is a broadly specific marker of 
B cells. We have focused on markers of the adap-
tive immune system as this is more relevant to our 
hypothesis, based on its antigen specificity. However, 
we also included the macrophage marker CD68 as a 
representative indicator of the myeloid lineage and 
innate compartment.
TMA scoring and data analysis
Scoring  was  performed  in  a  blinded  fashion  by 
an  experienced  breast  histopathologist  (PHW). 
  Immunostained TMA sections were initially scored 
by first assessing at low magnification and selecting 
the core with the highest density of positive cells. 
The number of positively stained tumor infiltrating 
leukocytes within the core area was then assessed 
through direct counting up to 20 or by estimation 
when  in  excess  of  this  number  (IHC  score,  range 
0–100). Distributions of TIL in primary and recurrent 
lesions were compared using Mann-Whitney T-tests. 
Changes in TIL status between primary and recur-
rent lesions were also compared by   categorizing the West et al
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Table 1. Clinical characteristics of the study cohort.
All IBTR cases True recurrencea new primarya
n = 24  n = 12  n = 12
Median age at diagnosis (years) 53 58 52
Median age at recurrence (years) 61 63 60
Median time to recurrence (months) 60 49 92
primary lesion
histology
  Infiltrating ductal 19 (79.2%) 10 (83.3%) 9 (75.0%)
  Mixed ductal and lobular 2 (8.3%) 1 (8.3%) 1 (8.3%)
  Other 3 (12.5%) 1 (8.3%) 2 (16.7%)
grade
 1 7 (29.2%) 4 (33.3%) 3 (25.0%)
 2 6 (25.0%) 2 (16.7%) 4 (33.3%)
 3 11 (45.8%) 6 (50.0%) 5 (41.7%)
Lymphovascular invasion
  negative 20 (83.3%) 10 (83.3%) 10 (83.3%)
  Positive 4 (16.7%) 2 (16.7%) 2 (16.7%)
estrogen receptors
  Positive 17 (70.8%) 9 (75.0%) 8 (66.7%)
  negative 5 (20.8%) 3 (25.0%) 2 (16.7%)
  Unknown 2 (8.3%) 0 (0.0%) 2 (16.7%)
Radiotherapy use
  Yes 21 (87.5%) 0 (0%) 2 (16.7%)
  no 3 (12.5%) 12 (100%) 10 (83.3%)
Systemic therapy use
  Chemotherapy 2 (8.3%) 1 (8.3%) 1 (8.3%)
  hormone therapy 7 (29.2%) 4 (33.3%) 3 (25.0%)
  Both 1 (4.2%) 0 (0.0%) 1 (8.3%)
  none 14 (58.3%) 7 (58.3%) 7 (58.3%)
IBTR lesion
grade
 1 7 (29.2%) 4 (33.3%) 3 (25.0%)
 2 6 (25.0%) 2 (16.7%) 4 (33.3%)
 3 11 (45.8%) 6 (50.0%) 5 (41.7%)
Lymphovascular invasion
  negative 17 (70.8%) 8 (66.7%) 9 (75.0%)
  Positive 7 (29.2%) 4 (33.3%) 3 (25.0%)
estrogen receptors
  Positive 17 (70.8%) 8 (66.7%) 9 (75.0%)
  negative 5 (20.8%) 2 (16.7%) 3 (25.0%)
  Unknown 2 (8.3%) 2 (16.7%) 0 (0.0%)
Radiotherapy use
  Yes 2 (8.3%) 0 (0.0%)  2 (16.7%)
  no 22 (91.7%) 12 (100.0%) 10 (83.3%)
Systemic therapy use
  Chemotherapy 3 (12.5%) 1 (8.3%) 2 (16.7%)
  hormone therapy 9 (37.5%) 4 (33.3%) 5 (41.7%)
  Both 2 (8.3%) 0 (0.0%) 2 (16.7%)
  none 10 (41.7%) 7 (58.3%) 3 (25.0%)
note: aChi-square comparisons between TR and nP, all P . 0.05.
  differences between their TIL IHC scores as increased, 
unchanged, or decreased in the recurrent lesion, and 
differences  were  assessed  by  chi  squared  test  for 
trend. An increase or decrease in TIL between pri-
mary and recurrent lesions was assigned when there 
was a difference in TIL score of 50% or more in the 
recurrent lesion, provided at least one of each lesion 
pair manifested a TIL score above a minimum thresh-
old of 5. All analyses were two-sided and performed 
using Prism 5 software   (GraphPad, La Jolla, CA).immune response to in-breast tumor recurrence
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TYPE
Change of
histological subtype
New Primary
(NP)
GRADE
Change from III to I
New Primary
(NP)
ER
Change from – to +
New Primary
(NP)
New Primary
(NP)
True Recurrence
(TR)
YES
NO YES
YES
YES
NO
NO
NO
LOCATION
Distinct or >3cm
from primary
Figure 1. Chart of the four-step clinical algorithm used to classify iBTRs as True Recurrence (TR) versus new Primary (nP) based on change in histology, 
grade, estrogen receptor status, and location.
Table 2. Primary antibodies used for immunohistochemistry.
Antigen clone supplier source concentration
CD3 RM-9107 Lab vision Rabbit 1/150
CD8 RM-9116 Lab vision Rabbit 1/100
CD4 MS-1528 Lab vision Mouse 1/10
FOXP3 eBio7979 eBioscience Mouse 1/50
CD25 4C9 Lab vision Mouse 1/40
TiA1 TiA-1 Abcam Mouse 1/50
CD20 Polyclonal, Catalogue # RB-9013 Lab vision Rabbit 1/250
CD68 Pg-M1 Lab vision Mouse 1/50
Results
Clinical classification of true recurrence 
vs. new primary
The  clinical  characteristics  of  primary  tumors  and 
IBTR  lesions  in  the  whole  exploratory  cohort  and 
according  to  TR  vs.  NP  classification  are  summa-
rized in Table 1. The distribution of characteristics 
and proportions of TR and NP IBTRs was similar to 
that seen in the entire cohort as previously reported.25 
Most patients were classified as NP on the basis of a 
change in location and most showed similar biological 
features. Among 12 cases classified as NP, the NP des-
ignation was made on the basis of tumor location in 
eight cases, change in histologic type in two cases, 
and change in ER status in two cases. There were no 
NPs classified on the basis of change in grade in this 
cohort. There were no significant differences in the 
distributions of histologic type, grade, ER status, lym-
phovascular invasion, radiotherapy use, or systemic 
therapy use between TR and NP cases (all P . 0.05).West et al
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Primary and iBTR tumors show no 
overall difference in immune response
TIL  markers  were  assessed  by  immunohistochemis-
try  in  the TMA  constructed  from  primary  and  IBTR 
tumors for each study subject. Representative examples 
of immunostaining for CD8 and CD68 in both primary 
and  IBTR  lesions  are  shown  for  two  cases  (Fig.  2). 
Primary  and  IBTR  tumor  groups  showed  no  signifi-
cant differences in mean levels of markers of adaptive 
(CD3,  CD8,  CD4,  CD25,  FOXP3,  TIA1,  CD20)  or 
innate (CD68) responses when assessed for the entire 
cohort (Fig. 3A). Primary and IBTR tumor groups were 
then reassessed after the latter had been classified by the 
decision rule clinical algorithm into putative NP or TR 
type IBTRs. Although not statistically significant, levels 
of CD3+ and CD8+ TIL tended to be lower in NP lesions 
compared to NP-associated primaries (Fig. 3B). In contrast, 
these cells were often more prevalent in TR lesions relative 
to TR-associated primaries (Fig. 3C). Compared to primary 
tumors, the median levels of CD8+ TIL were 3.3 fold lower 
in NP lesions and 2.5 fold higher in TR lesions.
Primary and iBTR tumors show different 
patterns of change between cases with 
nP and TR type recurrences
To further explore the trends described above, the 
pattern  of  changes  in  TIL  levels  between  primary 
and recurrent lesions within individual patients was 
  analyzed in a categorical analysis. IBTR TIL response 
was  considered  to  be  significantly  different  from 
the matched primary if the levels differed by 50% or 
more (Table 3). Although not all pairs were assessable 
due to missing cores, over half (4/7) of TR associated 
cases had increased CD3+ and CD8+ TIL in the recur-
rent lesion, while only one case had decreased levels 
and two cases showed no change. In contrast, none of 
the cases involving NPs had increased levels of CD3+ 
or CD8+ TIL in the recurrent lesions, while up to half 
had decreased levels. Therefore, there were signifi-
cant differences in the pattern of changes in CD3+ 
(P = 0.0201) and CD8+ (P = 0.0339) TIL responses 
between primary tumors and TR or NP IBTRs.
iBTR nP type tumors show reduced TiL 
compared to iBTR TR type tumors
Consistent  with  the  above  results,  comparison  of 
overall TIL levels between the two types of IBTR 
lesion  (Fig.  4A)  revealed  significantly  higher  TIL 
levels in TR compared to NP type recurrences for 
CD3+ (P = 0.0136) and CD8+ (P = 0.0092) TIL, as 
well  as  for  one  other  lymphocyte  marker,  CD25 
(P = 0.0159). The most striking difference was with 
respect to CD8+ TIL, the mean level of which was 
38.7 (95% CI 9.6–67.7) in TR lesions, compared to 
True Recurrence case
Primary
H&E
CD8
CD68
IBTR Primary IBTR
New Primary case
Figure 2. Illustrative examples of two cases of primary tumors with the corresponding IBTR tumors. Cases were classified as TR IBTR (left) or NP IBTR 
(right). Panels show H&E, CD8, and CD68 immunohistochemical staining for primary and IBTR tumors in each case (original magnification 10× for h&e 
and 20× for CD3 and CD68).immune response to in-breast tumor recurrence
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Figure 3. Box and whisker plots comparing TiL levels between primary (white) and iBTR (gray) lesions for the entire cohort (A) or between primary and 
iBTR lesions for nP (B) and TR cases (c). Whiskers represent minimum and maximum TiL counts.
only 3.9 (95% CI 0.3–7.5) in NP lesions. When pri-
mary tumors were classified on the basis of the type 
of IBTR with which they were associated, no differ-
ence was seen between subgroups of primary lesions 
for any   markers (Fig. 4B). Therefore, while all pri-
mary  lesions  had  comparable  levels  of  leukocyte 
  infiltration, TIL levels in their associated recurrences 
differed on the basis of TR or NP classification.
To explore the potential diagnostic value of CD3, 
CD8, and CD25 for identifying TR and NP IBTRs, 
we  constructed  receiver  operating  characteristic 
(ROC) curves for each TIL marker (data not shown). West et al
112  Breast Cancer: Basic and Clinical Research 2011:5
Table 3. Changes in TiL levels between primary and iBTR lesions for each TiL marker assessed.a
cD3b cD8b cD4 cD25 FOXp3 TIA1 cD20 cD68
iBTR-all increase 4 4 3 2 3 2 2 5
no change 6 6 11 9 7 8 12 5
Decrease 5 4 0 3 4 4 1 3
iBTR-TR increase 4 4 3 2 1 1 1 4
no change 2 2 4 3 5 4 5 1
Decrease 1 1 0 2 1 2 1 2
iBTR-nP increase 0 0 0 0 2 1 1 1
no change 4 4 7 6 2 4 7 4
Decrease 4 3 0 1 3 2 0 1
notes:  aValues indicate the number of iBTR cases with a $50% increase (‘increase’), less than a 50% change (‘no change’) or a $50% decrease 
(‘decrease’) in TiL levels relative to matched primary lesions. bSignificant difference between TR and NP tumors (P , 0.05) using chi2 test for trend.
CD8 was the strongest discriminator, with an AUC 
of 0.88 (P = 0.0082) and an optimal sensitivity and 
specificity  of  100%  and  78%,  respectively.  CD3 
(AUC = 0.84; P = 0.0128) and CD25 (AUC = 0.83; 
P  =  0.0210)  were  also  associated  with  significant 
ROC statistics. Consistent with its equivalent distri-
bution in TR and NP lesions, CD68 had no diagnos-
tic value in ROC analysis (AUC = 0.53; P = 0.8099). 
Lymphocytes expressing CD3, CD8, or CD25 may 
therefore be useful as diagnostic markers for distin-
guishing between TR and NP IBTRs.
Discussion
The  primary  aim  of  this  pilot  study  was  to  deter-
mine if TIL responses change with recurrence and 
are different between types of IBTR, and so might 
have potential as a clinical biomarker to identify dif-
ferent subtypes of IBTR. We have observed that TIL 
responses (CD3, CD8, and CD25) are often reduced in 
putative NP lesions, while these same TIL responses 
are  frequently  increased  in  TR  lesions.  Thus,  our 
results suggest that the pattern of change relative to 
the primary tumor and the level of the TIL response 
has potential as an approach to distinguish TR from 
NP IBTRs.
Primary and IBTR events occur many years apart 
(median  of  5  years  in  this  study  group)  and  sur-
gery for each event often occurs at different hospi-
tal centres. This contributes to significant challenges 
involved in conducting a study that depends on iden-
tifying patients who have had a recurrence and then 
obtaining archival paraffin block materials from past 
events.   Therefore,  very  few  studies  of  IBTR  have 
included analysis of tissue based biomarkers; indeed, 
the largest single institution based series has included 
blocks  from  only  57  cases.26  Our  study  here  of 
24 cases selected from a larger population based IBTR 
cohort is therefore intended as a pilot feasibility and 
hypothesis-  generating study to justify the effort and 
cost involved in conducting a larger investigation.
It is possible that the profile of this intratumoral 
immune response may differ between index tumors 
and different IBTR events because TRs and NPs are 
thought to have distinct origins. Limited studies of pri-
mary and concurrent metastasis have suggested that 
the responses seen between two lesions at two sites 
are typically similar.26,27 However, there is very little 
data on the actual changes observed in intratumoral 
immune responses between primary lesions and later 
relapses in solid tumors. This is partly attributable to 
a previous lack of appropriate cohorts/  samples and 
tools to interrogate the immune system in archival 
tissue samples representing primary tumors and their 
subsequent relapses. We can speculate that, compared 
to primary lesions, some TRs may harbour new muta-
tions  attributable  to  tumor  evolution  or  treatment 
effects.27,28 These mutations can create new immuno-
genic tumor-associated antigens and might increase 
the intratumoral adaptive immune response relative 
to the primary lesion. Radiation therapy to the pri-
mary lesion can also influence immunogenicity (eg, 
through  enhancement  of  major  histocompatibility 
complex expression by tumor cells29,30) and promote 
T cell homing (eg, by upregulation of chemokines 
and adhesion molecules31,32). By contrast, NP tumors 
might be expected to have evolved through developing 
mechanisms to escape an immune system educated to 
recognize the primary lesion, resulting in a reduced 
intratumoral immune response. This would be essen-
tial for NP tumors that feature a similar   spectrum of immune response to in-breast tumor recurrence
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antigens to primary lesions, as these tumors would be 
at risk of immunologic rejection from an early stage.
Our current study examined a limited number of 
immune cell markers. An important point to address 
in future studies is the specific lymphocyte phenotype 
associated with increased TIL in TR lesions. Tumor 
antigen specific memory cells are known to form in 
response to human breast cancer; for example, bone 
marrow-derived memory T cells specific to the breast 
cancer antigens Her2 and MUC1 were reported to 
reject autologous breast tumors in a xenotransplanta-
tion model.21 It is therefore possible that many of the 
intratumoral lymphocytes present in a TR lesion might 
be memory T cells initially generated in response to 
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Figure 4. Box and whisker plots comparing TiL levels between cases associated with TR (gray) and nP (white) iBTR lesions. (A) TiL levels in TR versus 
nP iBTR lesions. (B) TiL levels in primary lesions associated with TR versus nP iBTRs. 
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the primary tumor. Conversely, NP tumors that bear 
a different suite of antigens from the primary lesion 
would not be expected to elicit a response from mem-
ory cells generated against the primary tumor.
A potential caveat to our conclusions is that the 
approach used in this study to classify IBTRs could 
have  potentially  separated  two  distinct  biologi-
cal extremes of lesion related to tumor progression 
or treatment effects. However, in our classification 
approach changes in morphological type, grade, ER 
status, or location between primary tumors and recur-
rences were considered sequentially and the majority 
of NP type lesions were biologically similar. Indeed, 
most were classified as NP on the basis of distinct 
location alone. Thus, the differences in TIL popula-
tions observed with respect to NP and TR lesions are 
not likely due to biases arising from the classification 
scheme, but rather reflect underlying biological dif-
ferences between the two forms of IBTR. While our 
observations may have promise, the data have been 
generated from only a small sample size and should be 
replicated using tissue collected from larger cohorts. 
In addition, future studies should strive to assess a 
wider range of immunologic biomarkers, and iden-
tify optimal cutpoints for individual TIL markers and 
combinations thereof.
conclusions
As  a  consequence  of  the  increased  use  of  breast-
conserving therapy in modern clinical practice, IBTR 
will be an important aspect of breast cancer manage-
ment in the foreseeable future. Accurate identification 
of TR and NP IBTRs is challenging, however, and 
classical clinical and histopathological measures have 
thus far proven inadequate as diagnostic   criteria. We 
have expanded on classical approaches by addressing 
the problem from a biological perspective through 
assessment of host anti-tumor immunity, and provide 
novel  evidence  that  tumor-infiltrating  lymphocytes 
have potential as diagnostic biomarkers for distin-
guishing NP from TR IBTRs.
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